PALFORZIA is an oral immunotherapy indicated in patients aged 4 to 17 years, who have a confirmed diagnosis of peanut allergy. PALFORZIA may be continued in patients 18 years and older and must be used in conjunction with a peanut-avoidant diet.
“Today’s news of the EC approval represents the first-ever treatment option approved for peanut allergy in the EU and underscores our vision of providing end-to-end solutions as a driver of wellness and treatment, in the key growth areas of nutrition, metabolism, healthy aging and food allergy,” said Greg Behar, CEO of Nestlé Health Science.
Food allergies affect around 17 million people across Europe, with peanut allergy being one of the most common of those. In fact, peanut allergy doubled among children between 2005 and 2015, and the number of hospital admissions due to severe allergic reactions increased seven-fold.1 Severe reactions combined with the difficulty of avoiding peanut protein create an urgent need for treatment.
Andrew Oxtoby, President and CEO of Aimmune Therapeutics, said, “Now we turn our efforts toward working with health authorities to ensure access to this first-of-kind treatment for those children with peanut allergy for whom our product is appropriate as we prepare to launch in Germany and the UK in May 2021.”
